Epirubicin hydrochloride liposomal - CSPC ZhongQi Pharmaceutical Technology
Alternative Names: Epirubicin hydrochloride liposome injectionLatest Information Update: 29 Apr 2022
Price :
$50 *
At a glance
- Originator CSPC ZhongQi Pharmaceutical Technology
- Class Cytostatic antibiotics; Doxorubicins; Small molecules
- Mechanism of Action DNA intercalators; RNA synthesis inhibitors; Type II DNA topoisomerase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I Haematological malignancies; Solid tumours
Most Recent Events
- 28 Apr 2022 Phase-I clinical trials in Haematological malignancies in China (Parenteral) before April 2022 (CSPC Pharmaceutical Group pipeline, April 2022)
- 28 Apr 2022 Phase-I clinical trials in Solid tumours in China (Parenteral) before April 2022 (CSPC Pharmaceutical Group pipeline, April 2022)
- 22 Oct 2019 Preclinical trials in Solid tumours in China (Parenteral) before October 2019